Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Deal Watch

Uncertainty, austerity and Brexit

What does it mean for the life science sector?

Brexit Means Brexit

The differential destinations of post-Brexit pharma

- PMLiVE

AZ taps Ionis for another drug, this time in NASH

Will acquire the US pharma group’s antisense drug in a deal valued up to $330m

Working with our healthcare system more closely is vital

Bayer’s Lars Bruening on partnership working amid environmental challenges

- PMLiVE

MHRA: No change for pre-Brexit products after UK exits the EU

And UK plans to follow EU rules for an implementation period after March 2019

- PMLiVE

Health coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

Brexit talks threaten supply of medical technologies

As concern grows that the outcome could undermine the regulatory framework

- PMLiVE

UK pharma welcomes Brexit breakthrough

Calls for medicines regulation and supply to be a priority in talks' next stage

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

Research Partnership

- PMLiVE

MSD to create strong UK discovery centre in London

The pharma group aims to start operations by 2020

- PMLiVE

Amsterdam picked to host the European Medicines Agency

But regulator faces a “challenging” relocation project to depart from London

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links